MediciNova, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
MediciNova, Inc. (MNOV) holds an ST Score of 57.5 out of 100 (B-), with its strongest factor being Momentum (A) and its weakest Growth (C-). Analysts rate MNOV Buy across 4 ratings with a $6.00 average price target (+0.8% vs the current $3.32).
- Strongest
- MomentumA
- Weakest
- GrowthC-
All factor grades
- MomentumA
- Financial StrengthA-
- ProfitabilityB+
- ForecastB+
- ValuationC
- GrowthC-
- Piotroski2/9
Contact
MNOV stock: frequently asked questions
What is MNOV's ST Score?
MediciNova, Inc. (MNOV) has an ST Score of 57.5 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is MNOV a buy, sell, or hold?
Wall Street's consensus rating on MNOV is Buy based on 4 analyst ratings. Our own ST Score grades it B- (57.5/100). This is data, not investment advice — always do your own research.
What is MNOV's valuation grade?
MediciNova, Inc. (MNOV) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is MNOV's growth grade?
MediciNova, Inc. (MNOV) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is MNOV's profitability grade?
MediciNova, Inc. (MNOV) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is MNOV's financial strength grade?
MediciNova, Inc. (MNOV) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for MNOV?
The average analyst price target for MediciNova, Inc. (MNOV) is $6.00 from 4 analysts, which is +0.8% versus the recent price of $3.32.
What is MNOV's Piotroski score?
MediciNova, Inc. (MNOV) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.